Humabs BioMed Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
37
- Latest Deal Type
-
M&A
- Financing Rounds
-
1
Humabs BioMed General Information
Description
Developer of human monoclonal antibodies created to treat a wide range of serious infections in the human body. The company's human monoclonal antibodies have passed natural selection by the human immune system in response to viral and bacterial diseases, in addition, it also developed anti-infective immunotherapies for the treatment of induce protective and therapeutic immune responses which solutions are non-existent or inadequate, enabling patients and pharmaceutical companies to get drugs for the treatment of rare diseases.
Contact Information
Website
www.humabs.comCorporate Office
- Via Mirasole 1
- 6500 Bellinzona
- Switzerland
Corporate Office
- Via Mirasole 1
- 6500 Bellinzona
- Switzerland
Humabs BioMed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Humabs BioMed Comparisons
Industry
Financing
Details
Humabs BioMed Competitors (78)
One of Humabs BioMed’s 78 competitors is OncoResponse, a Venture Capital-Backed company based in Houston, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| OncoResponse | Venture Capital-Backed | Houston, TX | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Mestag Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Macomics | Venture Capital-Backed | Edinburgh, United Kingdom | ||||
| InflaRx | Formerly VC-backed | Jena, Germany |
Humabs BioMed Patents
Humabs BioMed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024182781-A1 | Coronavirus compositions and uses thereof | Inactive | 02-Mar-2023 | ||
| WO-2024118998-A2 | Engineered anti-sars-cov-2 antibodies and methods of using the same | Inactive | 01-Dec-2022 | ||
| WO-2024118998-A3 | Engineered anti-sars-cov-2 antibodies and methods of using the same | Inactive | 01-Dec-2022 | ||
| WO-2024112818-A1 | Engineered anti-sars-cov-2 antibodies and uses thereof | Inactive | 22-Nov-2022 | ||
| WO-2024102327-A1 | Using sparse electronic health records for predicting health outcome | Inactive | 07-Nov-2022 | G16H10/60 |
Humabs BioMed Signals
Humabs BioMed FAQs
-
When was Humabs BioMed founded?
Humabs BioMed was founded in 2004.
-
Where is Humabs BioMed headquartered?
Humabs BioMed is headquartered in Bellinzona, Switzerland.
-
What is the size of Humabs BioMed?
Humabs BioMed has 37 total employees.
-
What industry is Humabs BioMed in?
Humabs BioMed’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Humabs BioMed a private or public company?
Humabs BioMed is a Private company.
-
What is Humabs BioMed’s current revenue?
The current revenue for Humabs BioMed is .
-
Who are Humabs BioMed’s competitors?
OncoResponse, Virometix, Mestag Therapeutics, Macomics, and InflaRx are some of the 78 competitors of Humabs BioMed.
-
When was Humabs BioMed acquired?
Humabs BioMed was acquired on 25-Sep-2017.
-
Who acquired Humabs BioMed?
Humabs BioMed was acquired by Vir Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process